Guggenheim raised the firm’s price target on Illumina (ILMN) to $144 from $114 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for its covered Diagnostics and Life Sciences Tools companies to reflect recent updates from the companies after meetings with management teams.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target raised to $130 from $112 at Canaccord
- Illumina price target raised to $130 from $105 at JPMorgan
- Illumina price target raised to $110 from $100 at Barclays
- Illumina, MyOme announces collaboration, investment by Illumina into MyOme
- Illumina Completes $500M Notes Offering for Expansion